AKAbdulselam Karaduman

Abdulselam Karaduman

*This is an algorithmically generated author record based on publicly available information.

Abdulselam Karaduman has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Colchicine Use Is Associated with Shorter ICU Stay and Lower FFP Transfusion Requirements After CABG

    by Mehmet Burak Gulcan, Mehmet Ali Kaygın, Aycan Mutlu Yaganoglu, Ziya Yıldız, Abdulselam Karaduman, Suleyman Aycan, Ozgur Dag

    Background: Colchicine has demonstrated anti-inflammatory and cardiovascular benefits in patients with coronary heart disease. However, evidence regarding its effects on postoperative inflammation and early clinical outcomes following coronary artery bypass grafting (CABG) remains limited. Objective: We aimed to evaluate the association between perioperative low-dose colchicine use and postoperative clinical outcomes, transfusion requirements, complications, and inflammatory markers in patients undergoing elective on-pump CABG. Methods: This retrospective study included 151 patients who underwent elective on-pump CABG: 81 received colchicine (0.5 mg once daily for 3 days preoperatively and 10 days postoperatively) and 70 did not receive colchicine in the past period. The primary clinical outcomes included ICU and total hospital length of stay, erythrocyte and fresh frozen plasma (FFP) transfusion requirements, wound complication, and surgical revision. Postoperative day 5 laboratory parameters included C-reactive protein, white blood cell (WBC) count, systemic immune-inflammation index (SII), and albumin. Between-group comparisons were performed using Student’s or Welch’s t tests and Pearson’s chi-square or Fisher’s exact tests, as appropriate. Results: Baseline age and sex distribution were similar between the groups. The colchicine group had a significantly shorter ICU stay than the control group (4.28 ± 1.95 vs. 5.83 ± 3.04 days; mean difference, −1.54 days; 95% CI, −2.38 to −0.71; p < 0.001). FFP transfusion requirements were also significantly lower in the colchicine group (3.49 ± 1.24 vs. 8.13 ± 3.97 units; mean difference, −4.63 units; 95% CI, −5.62 to −3.65; p < 0.001). Postoperative WBC counts were lower with colchicine (9.44 ± 3.31 vs. 10.78 ± 4.04 × 109/L; p = 0.027). Total hospital stay, erythrocyte transfusion requirements, other inflammatory parameters, wound complication rates, and surgical revision rates did not differ significantly between the groups. Conclusions: Perioperative low-dose colchicine was found to be in relation with shorter ICU stays, lower FFP transfusion requirements, and reduced postoperative WBC counts following elective on-pump CABG according to this retrospective study. Prospective randomized studies are required to confirm these findings and to determine whether colchicine improves early postoperative outcomes.

  • Open Access

    Association of Perioperative Colchicine Use with Morbidity and Inflammation in Heart Valve Surgery

    by Mehmet Burak Gulcan, Mehmet Ali Kaygın, Aycan Mutlu Yaganoglu, Ziya Yıldız, Abdulselam Karaduman, Suleyman Aycan, Ozgur Dag

    Background and Objectives: Valvular heart disease (VHD) is a major cause of morbidity and mortality worldwide, and valve replacement surgery performed under cardiopulmonary bypass (CPB) with full sternotomy remains an important treatment modality. Colchicine has well-established anti-inflammatory effects in ischemic heart disease and pericardial disease, but its association with postoperative morbidity in patients undergoing valvular heart surgery has not been well studied. This study aimed to investigate the association of perioperative colchicine use with clinical morbidity and inflammatory parameters in patients undergoing valvular heart surgery with CPB. Materials and Methods: In this retrospective study, 82 patients who underwent elective on-pump valvular heart surgery through full sternotomy were divided into a control group (n = 42) who did not receive colchicine and a colchicine group (n = 40) who received oral colchicine (0.5 mg once daily) for three days before and ten days after surgery. Demographic, clinical, and laboratory data, including length of hospital and intensive care unit (ICU) stay, transfusion requirements, sternal wound complication, surgical re-exploration, and inflammatory parameters on postoperative day 5 (C-reactive protein [CRP], white blood cell count, albumin, platelet-to-lymphocyte ratio [PLR], and neutrophil-to-lymphocyte ratio [NLR]), were compared between the groups. Results: Length of ICU stay was significantly shorter in the colchicine group than in the control group (4.1 ± 1.6 vs. 5.3 ± 2.4 days; p = 0.009), and fresh frozen plasma transfusion requirement was significantly lower in the colchicine group (4.2 ± 2.1 vs. 6.9 ± 3.3 units; p < 0.001). Total hospital stay, erythrocyte transfusion requirement, and inflammatory parameters (CRP, white blood cell count, NLR, PLR, and albumin) did not differ significantly between the two groups (all p > 0.05). Conclusions: Perioperative colchicine was associated with a shorter ICU stay and a reduced requirement for fresh frozen plasma transfusion in patients undergoing valvular heart surgery with CPB, suggesting that colchicine may have a potential role in this surgical population. After correction for multiple comparisons, the difference in ICU length of stay was no longer statistically significant. Larger prospective studies are warranted to confirm these findings.


  • Open Access

    Colchicine Use Is Associated with Shorter Intensive Care Unit Stay and Lower Fresh Frozen Plasma Transfusion Requirements After Coronary Artery Bypass Grafting

    by Mehmet Burak Gulcan, Mehmet Ali Kaygın, Aycan Mutlu Yaganoglu, Ziya Yıldız, Abdulselam Karaduman, Suleyman Aycan, Ozgur Dag

    Background: Colchicine has demonstrated anti-inflammatory and cardiovascular benefits in patients with coronary heart disease. However, evidence regarding its effects on postoperative inflammation and early clinical outcomes following coronary artery bypass grafting (CABG) remains limited. Objective: To evaluate the association between perioperative low-dose colchicine use and postoperative clinical outcomes, transfusion requirements, complications, and inflammatory markers in patients undergoing elective on-pump CABG. Methods: This retrospective study included 151 patients who underwent elective on-pump CABG: 81 received colchicine (0.5 mg once daily for 3 days preoperatively and 10 days postoperatively), and 70 did not receive colchicine. The primary clinical outcomes included ICU and total hospital length of stay, erythrocyte and fresh frozen plasma (FFP) transfusion requirements, wound infection, and surgical revision. Postoperative day 5 laboratory parameters included C-reactive protein, white blood cell (WBC) count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and albumin. Between-group comparisons were performed using Student’s or Welch’s t test and Pearson’s chi-square or Fisher’s exact test, as appropriate. Results: Baseline age and sex distribution were similar between the groups. The colchicine group had a significantly shorter ICU stay than the control group (4.28±1.95 vs 5.83±3.04 days; mean difference, −1.54 days; 95% CI, −2.38 to −0.71; P< 0.001). FFP transfusion requirements were also significantly lower in the colchicine group (3.49±1.24 vs 8.13±3.97 units; mean difference, −4.63 units; 95% CI, −5.62 to −3.65; P< 0.001). Postoperative WBC counts were lower with colchicine (9.44±3.31 vs 10.78±4.04×10⁹/L; P=0.027). Total hospital stay, erythrocyte transfusion requirements, other inflammatory parameters, wound infection rates, and surgical revision rates did not differ significantly between the groups. Conclusion: Perioperative low-dose colchicine use was associated with shorter ICU stays, lower FFP transfusion requirements, and reduced postoperative WBC counts following elective on-pump CABG. Prospective randomized studies are required to confirm these findings and determine whether colchicine improves early postoperative outcomes.